Structural advantages and material innovation: mPEG-X (including: mPEG-PCL, mPEG-PLLA, mPEG-PDLLA, mPEG-PLGA) is a linear amphiphilic triblock copolymer, which has both hydrophilic and hydrophobic synergistic effects, forming a nanocarrier with controllable biodegradability and excellent biocompatibility.

High drug load: Efficient loading of water-insoluble drugs (such as paclitaxel, docetaxel, etc.) through the hydrophobic core to increase drug loading;

> Sustained release characteristics: slow degradation of PCL/PLA/PLGA and other chain segments to achieve sustained release for several weeks, significantly reducing the sudden release effect;

Targeted synergy: PEG modification of nanoparticle surfaces can prolong blood half-life and enhance tumor tissue enrichment through EPR effects.

can bind with gene molecules through electrostatic interaction or covalent bonds to form gene vector complexes, protect genes from degradation by nucleases in vivo, and at the same time deliver genes specifically to target cells through their targeting function to achieve efficient gene expression and therapeutic effects.

• Relying on the polyethylene glycolation technology platform and the targeted nanopreparation platform, DiQi Pharmaceuticals provides full-chain services from molecular design to industrialization.

• 1. Customized development: support flexible adjustment of molecular weight range of 2-40kDa to meet the needs of different dosage forms such as microspheres, nanoparticles, micelles, etc.; End-group functionalized modifications (such as carboxyl, amino, maleimide, etc.) to achieve antibody conjugation or targeted ligand modification.
• 2. International standard production: compliant with cGMP specifications, support CDE/FDA excipient registration;
• 3. Strict quality control: Multi-dimensional testing such as NMR, GPC, GC, etc. is used to ensure molecular weight distribution and purity.